Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Trial Purpose and Description
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- 18 Years - 65 Years
- Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),
- Women who are pregnant, nursing or unwilling to use appropriate birth control
measures during study participation.
- Stanley Medical Research Institute
- Yale University
- February 2009
- Last Updated:
- July 17, 2012
- Study HIC#:
Clinicaltrials.gov ID: NCT00588731